The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-Germany defends AstraZeneca pivot as key to speeding vaccinations

Fri, 07th May 2021 09:54

* All adults now free to get AZ shot, on doctor's advice

* Gap between doses can be as little as 4 weeks

* Experts warn on reduced efficacy with shorter gap

* Third wave of pandemic "appears to be broken" - minister
(Recasts to lead on AstraZeneca shift)

By Douglas Busvine and Paul Carrel

BERLIN, May 7 (Reuters) - Health Minister Jens Spahn on
Friday defended another U-turn by Germany on the AstraZeneca
vaccine, saying making it available to all adults who
want it would protect more people against COVID-19 more quickly.

Spahn announced late on Thursday that Germany would make
AstraZeneca available to all adults, subject to consulting a
doctor, and allow people to get a second shot as soon as four
weeks after the first.

The move comes with an eye to the summer holidays and
coincides with the rapid passage of legislation that would free
those fully vaccinated from social distancing measures imposed
to fight the pandemic.

Germany had previously limited the shot from the
Anglo-Swedish drugmaker to people over 60 after post-vaccination
monitoring found rare - and sometimes fatal - cases of blood
clotting, with younger women disproportionately affected.

Before that, its vaccine oversight body had said the shot
could not be given to the elderly because of a lack of data from
clinical trials.

With 70% of older people now inoculated and Germany's
vaccination drive gaining momentum, Spahn said the latest step
on AstraZeneca would offer a vaccination option to people who
would otherwise have to wait.

"We are convinced this offer is attractive for those who
would otherwise not get vaccinated so quickly," Spahn told a
news conference, adding that 1 million AstraZeneca doses would
be sent to doctors' practices next week.

THE SOONER, THE WORSE?

The decision by the federal government follows moves by
several German states to make AstraZeneca more widely available
and comes as the pace of giving shots of mainstay vaccines from
BioNTech/Pfizer and Moderna picks up.

The share of the population that has received a first
vaccine shot has reached 31.5%, with 900,000 getting a dose on
Thursday, putting Germany "in the fast lane" by international
standards, said Spahn.

He said the third wave of the coronavirus pandemic "appears
to be broken" while Germany's top public health official, Lothar
Wieler, said infections were falling across all age groups
thanks to social distancing and the progress on vaccinations.

Confirmed cases rose by 18,485 on Friday, with 284
fatalities, while the seven-day incidence fell to 125.7 cases
per 100,000 people, data from the Robert Koch Institute showed.

However, experts criticised the decision to allow people to
receive the AstraZeneca vaccine at shorter intervals, saying
studies had shown its efficacy to be only around 55% with a
four-week gap and 80% with a 12-week delay to the second shot.

"We have to make it clear that if people shorten the gap
between AstraZeneca doses to enjoy greater freedom of movement
sooner, they are doing so at the cost of their immune
protection," said Carsten Watzl, professor of immunology at the
Dortmund Technical University.

Spahn said this was a decision that people should take with
proper advice, a view seconded by Robert Koch Institute head
Wieler.

"We know that the longer the gap before the second shot the
better the protection," Wieler said. "This is an informed
decision people can take in consultation with their doctors."
(Writing by Douglas Busvine
Editing by Gareth Jones)

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.